Tìm theo
MDV3100
Thuốc Gốc
Small Molecule
MDV3100 is a small molecule compound developed to treat hormone-refractory prostate cancer. MDV3100, which was rationally designed based on a breakthrough discovery, directly addresses a key mechanism that leads to prostate cancer cell death. MDV3100 may block both hormone-refractory and hormone-sensitive prostate cancer better than currently available therapies.
Cơ Chế Tác Dụng : MDV3100 is a small molecule compound developed to treat hormone-refractory prostate cancer. MDV3100, which was rationally designed based on a breakthrough discovery, directly addresses a key mechanism that leads to prostate cancer cell death. MDV3100 may block both hormone-refractory and hormone-sensitive prostate cancer better than currently available therapies. MDV3100 is the lead development candidate from a library of approximately 170 small molecules licensed by Medivation. These molecules were rationally designed to treat hormone-refractory prostate cancer by inhibiting the androgen receptor (AR) in a different manner from currently approved AR antagonist drugs, which are ineffective in treating prostate cancers that have become hormone-refractory.
Chỉ Định : Investigated for use/treatment in prostate cancer.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05094
... loading
... loading